Laboratorio de Investigaciones Básicas y Aplicadas, Escuela de Bioanálisis, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela.
Obesity (Silver Spring). 2010 Oct;18(10):2023-9. doi: 10.1038/oby.2010.9. Epub 2010 Feb 4.
Plasma phospholipases A(2) (PLA(2)) hydrolyze phospholipids of circulating lipoproteins or deposited in arteries producing bioactive lipids believed to contribute to the atherosclerotic inflammatory response. PLA(2)(s) are elevated in obesity and type 2 diabetes (T2D) but it is not clear which of these conditions is the cause since they frequently coexist. This study attempts to evaluate if high plasma PLA(2)(s) activities and markers of their effects in lipoproteins are associated with obesity or T2D diabetes, or with both. Total PLA(2) and Ca(2+)-dependent and -independent activities, lipids, lipoproteins, apoAI, and apoB apolipoproteins and affinity of apoB-lipoproteins for arterial proteoglycans were measured, as well as Inflammation markers. These parameters were evaluated in plasma samples of four groups: (i) apparently healthy controls with normal BMI (nBMI), (ii) obese subjects with no T2D, (iii) patients with T2D but with nBMI, and (iv) obese patients with T2D. PLA(2) activities were measured in the presence and absence of Ca(2+) and in the presence of specific inhibitors. Obese subjects, with or without T2D, had high activities of total PLA(2) and of Ca(2+)-dependent and Ca(2+)-independent enzymes. The activities were correlated with inflammation markers in obese subjects with and without diabetes and with alterations of low-density lipoproteins (LDLs) that increased their affinity for arterial proteoglycans. Ca(2+)-dependent secretory (sPLA(2)) enzymes were the main responsible of the obesity-associated high activity. We speculate that augmented PLA(2)(s) activity that increases affinity of circulating LDL for arterial intima proteoglycans could be another atherogenic component of obesity.
血浆磷脂酶 A(2) (PLA(2)) 水解循环脂蛋白或沉积在动脉中的磷脂,产生生物活性脂质,据信这些脂质有助于动脉粥样硬化炎症反应。肥胖症和 2 型糖尿病 (T2D) 患者的 PLA(2)(s) 水平升高,但由于这些情况经常同时存在,尚不清楚哪种情况是原因。本研究试图评估高血浆 PLA(2)(s) 活性及其在脂蛋白中的作用标志物是否与肥胖或 T2D 糖尿病有关,或者与两者都有关。测量了总 PLA(2)和 Ca(2+)依赖性和非依赖性活性、脂质、脂蛋白、载脂蛋白 AI 和载脂蛋白 B 载脂蛋白以及载脂蛋白 B-脂蛋白与动脉蛋白聚糖的亲和力,以及炎症标志物。这些参数在四个组的血浆样本中进行了评估:(i) 具有正常 BMI 的健康对照者(nBMI),(ii) 无 T2D 的肥胖者,(iii) 无 nBMI 的 T2D 患者,以及 (iv) 肥胖伴 T2D 的患者。在存在和不存在 Ca(2+)的情况下以及在存在特异性抑制剂的情况下测量 PLA(2) 活性。肥胖患者,无论是否患有 T2D,均具有高总 PLA(2)和 Ca(2+)-依赖性和 Ca(2+)-非依赖性酶活性。这些活性与肥胖患者(无论是否患有糖尿病)的炎症标志物相关,并且与 LDL(低密度脂蛋白)的改变相关,这增加了它们与动脉蛋白聚糖的亲和力。Ca(2+)-依赖性分泌型 (sPLA(2)) 酶是肥胖相关高活性的主要原因。我们推测,增加的 PLA(2)(s) 活性增加了循环 LDL 对动脉内膜蛋白聚糖的亲和力,可能是肥胖的另一个致动脉粥样硬化成分。